Albert Montana-Perez

Palma, PM, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Immune biomarkers of increased infection risk in multiple myeloma.

Immune biomarkers of increased infection risk in multiple myeloma.

Journal: Blood

Published: September 22, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances

Published: September 18, 2025

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Real-world evidence of measurable residual disease assessment in multiple myeloma.

Journal: Blood advances

Published: September 18, 2025

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 17, 2023

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

Journal: Nature communications

Published: November 25, 2022

Identification of Two Novel EPOR Gene Variants in Primary Familial Polycythemia: Case Report and Literature Review.

Identification of Two Novel EPOR Gene Variants in Primary Familial Polycythemia: Case Report and Literature Review.

Journal: Genes

Published: August 10, 2022

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.

Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 17, 2022

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.

Journal: Blood advances

Published: May 06, 2022

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.

Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.

Journal: Blood

Published: November 17, 2020

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.

Journal: Leukemia

Published: January 16, 2020

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis.

Journal: Leukemia

Published: November 19, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026